Citations

Clear

61 citation(s) found for "Pasha, SF".

Most of moderate to severe ulcerative colitis patients in academic clinical practice still do not qualify for randomized controlled trials
Elmasry, Sandra, Pasha, Shabana, Kaur, Manreet , Leighton, Jonathan A. , Gurudu, Suryakanth, Ha, Christina , Elmasry, Sandra , Gurudu, Suryakanth R, Ha, Christina , Pasha, Shabana F.

Mayo Clinic

Crohn’s & Colitis 360 | August 4, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag092 | PMID 42633268 Get It

Abstract Background While biologic and small molecule therapies have expanded treatment options for moderate to severe ulcerative colitis (UC), prior research revealed that only 26% of patients in routine practice would have qualified for pivotal randomized controlled trials (RCTs) due to stringent eligibility criteria. This study aimed to evaluate contemporary clinical trial eligibility for UC patients in a tertiary care setting based on more recently approved therapies. Methods We performed a retrospective cohort study of adult patients with moderate to severe UC (total Mayo score ≥6) seen between January 2022 and February 2023. Inclusion and exclusion criteria from seven phase III RCTs conducted between 2012 and 2022 (eg, VARSITY, UNIFI, OCTAVE, LUCENT) were applied to determine patient eligibility and identify reasons for ineligibility. Results Of 150 patients (mean age 44.9 years; 55.7% male), only 42.7% were eligible for at least one RCT. The most common exclusion factor was current or prior medication use, followed by anemia, dysplasia, and disease extent. Trial eligibility did not significantly differ by age, gender, or disease duration. Conclusions Despite modest improvements since 2012, over half of real-world UC patients remain ineligible for current RCTs. Expanding inclusion criteria, especially regarding prior medication exposure, and adopting more inclusive trial designs may enhance external validity. Addressing disparities in trial access and participation remains essential to ensuring equitable representation and improving clinical applicability of RCT findings.
Public Health Limits of Medical Freedom
Hodge, James, Ghaith, Summer , Pasha, Amirala S. , Pasha, Amirala S , Hodge, James G.

Mayo Clinic

Journal of Law, Medicine & Ethics | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1017/jme.2026.10265 | PMID 42130399 Get It

Abstract Through emerging interpretations of individual “medical freedoms,” a panoply of state legislative bills seeks to undermine long-standing public health and health care requirements including recommendations to test, screen, treat, and vaccinate persons. To the extent these bills could upend decades of laws and policies protecting individual and communal health, especially among vulnerable individuals, they threaten the health — and freedoms — of all persons.
OTHR-01. Endoscopic treatment vs Ventriculoperitoneal shunting for failed ETVs in pediatric patients with Hydrocephalus: A systematic review
Ahmed, Ikhlas , Choudry, Usama Khalid , Khan, Saad , Nasir, Roua , Haque, Minza, Noor, Ahmad, Pasha, Muhammad Saad, Arif, Aabiya , Akhunzada, Naveed Zaman, Godfrey, Oswin, Nathani, Karim Rizwan , Sangah, Abdul Basit

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.260 Get It

Abstract Background Hydrocephalus, the abnormal buildup of cerebrospinal fluid (CSF) in the brain’s ventricles, makes pediatric neurosurgery difficult. Endoscopic Third Ventriculostomy (ETV) and Ventriculoperitoneal Shunting (VPS) are the basic treatments, however unsuccessful ETV management is disputed. This study aims to compare RE-ETV with VPS in pediatric hydrocephalus patients after unsuccessful ETV. Methods A comprehensive literature review was performed using PubMed, Embase, and Cochrane Library. The review covered pediatric RE-ETV or VPS trials following ETV failure. Success rates, complications, failure timings, and reoperation rates were extracted. The Cochrane Collaboration’s risk of bias instrument (RoB 2.0) and Critical Appraisal Skills Programme (CASP) were utilized to assess quality of studies. Results 40 articles were chosen for comprehensive full-text evaluation. Nine publications specifically addressing the topic of Re-ETV and/or VPS placement after the failure of original ETV were identified as acceptable for the review. A data set of 663 patients was assessed. Re-ETV was carried out in 220 patients (33.18%) and VPS Placement was done in 443 patients (66.81%). The primary ETV failure rates ranged from 16.6% to 60.89%. There was a larger failure rate of Re-ETV (74.98%) compared to VPS (22.26%) showing that VPS is often more effective as a secondary intervention. The presence of bleeding during primary ETV suggested more benefit from VPS placement rather than Re-ETV (p < 0.05). Conclusions VPS is more commonly employed than RE-ETV in pediatric patients after unsuccessful ETV. Although RE-ETV provides a less invasive technique, it has a greater failure rate. However, owing to inadequate evidence on VPS failure post-ETV, additional research is recommended. Future research should concentrate on enhancing the evidence foundation to aid clinical decision-making in treating hydrocephalus post-ETV failure.
At Two Tables
Noland, Shelley S. , Pasha, Terouz

Mayo Clinic

Journal of Bone and Joint Surgery | December 3, 2025 | Volume: 108 | Issue: 8 | Pages: 549-550

10.2106/jbjs.25.00944 | PMID 41337568 Get It

SURP-02. Re-ETV versus Ventriculoperitoneal Shunting in Failed ETV in Pediatric Patients with Hydrocephalus: A Systematic Review
Ahmed, Ikhlas , Choudry, Usama Khalid , Basit, Abdul , Nasir, Roua , Noor, Ahmed , Pasha, Muhammad Saad, Akhunzada, Naveed Zaman, Arif, Aabiya , Godfrey, Oswin, Nathani, Karim Rizwan , Khan, Saad Akhtar , Haque, Minza, Noor, Ahmed

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v418-v419

10.1093/neuonc/noaf201.1657 Get It

Abstract INTRODUCTION Hydrocephalus in pediatric patients is commonly treated with endoscopic third ventriculostomy (ETV) or ventriculoperitoneal shunting (VPS). When primary ETV fails, clinicians must decide between repeat ETV (Re-ETV) and VPS placement. However, the optimal secondary intervention remains debated. Objective: To compare the efficacy and outcomes of Re-ETV versus VPS placement following failed primary ETV in pediatric hydrocephalus. METHODS We conducted a systematic review following PRISMA guidelines. Searches of PubMed, Embase, and the Cochrane Library identified English-language studies (2001–2023) reporting on Re-ETV or VPS after failed primary ETV in patients aged 0–18 years. Comparative studies, including randomized controlled trials, cohort studies, and prospective designs were eligible. Two independent reviewers screened titles, abstracts, and full texts; extracted data on sample size, intervention rates, failure rates, and complications; and assessed study quality using RoB 2.0 and CASP tools. Pooled descriptive statistics and odds ratios (OR) were calculated for secondary intervention failure. RESULTS Nine studies (n = 663) met inclusion criteria. Re-ETV was performed in 220 patients (33.2%) and VPS in 443 (66.8%). Primary ETV failure rates ranged from 16.6% to 60.9% (mean 40.6%). Re-ETV exhibited a pooled failure rate of 74.98%, whereas VPS failure was 22.26% (OR 4.86; 95% CI 3.21–7.38; p < 0.05). Hemorrhagic etiology during primary ETV significantly favored VPS over Re-ETV (p < 0.05). Time to secondary failure averaged 15.8 ± 21.7 months, with broad inter-study variability. CONCLUSION VPS placement demonstrates a substantially lower failure rate than Re-ETV as a secondary intervention after primary ETV failure in pediatric hydrocephalus. Nevertheless, variability in patient age, etiology, and follow-up underscores the necessity of individualized decision-making. Prospective trials with standardized outcome measures are warranted to refine secondary treatment guidelines.
Re-endoscopic third ventriculostomy versus ventriculoperitoneal shunting in failed endoscopic third ventriculostomy in pediatric patients with hydrocephalus: A systematic review
Ahmed, Ikhlas , Choudry, Usama Khalid , Basit, Abdul , Nasir, Roua , Noor, Ahmed , Pasha, Muhammad Saad, Arif, Aabiya , Akhunzada, Naveed Zaman, Godfrey, Oswin, Sangah, Abdul Basit , Nathani, Karim Rizwan , Khan, Saad Akhtar , Haque, Minza, Noor, Ahmed

Mayo Clinic

Surgical Neurology International | May 30, 2025 | Volume: 16 | Issue: No issue available | Pages: 205

10.25259/sni_1111_2024 | PMID 40469369 Get It

Background: The objective of this research article is to compare endoscopic treatment versus shunting procedures for failed endoscopic third ventriculostomies (ETVs) in pediatric patients with hydrocephalus. Methods: We did a systematic review based on preferred reporting items for systematic reviews and meta-analyses guidelines on Studies involving pediatric patients (aged 0–18 years) diagnosed with hydrocephalus, reporting on the use of repeat ETV (Re-ETV) or Ventriculoperitoneal shunting (VPS) as a treatment option following failed ETV. Comparative studies, including randomized controlled trials, cohort studies, and any prospective studies, are included. Studies published in the English language conducted between 2001 and 2023 are included. Results: Forty articles were selected for full-text review. Out of which nine articles that clearly addressed the topic of Re-ETV and/or VPS placement after failure of primary ETV were deemed suitable for analysis. A data set of 663 patients was analyzed. Re-ETV was done in 220 patients (33.18%) and VPS Placement was done in 443 patients (66.81%). The primary ETV failure rates ranged from 16.6 to 60.89%. There was a higher failure rate of Re-ETV (74.98%) compared to VPS (22.26%) indicating that VPS is generally more successful as a secondary intervention. The presence of hemorrhage during primary ETV suggested more benefit from VPS placement rather than Re-ETV (P < 0.05). Conclusion: Our systematic review suggests that VPS placement is the more prevalent choice after primary ETV failure, likely due to its higher overall success rate and the nature of complications. The wide variability in failure rates and follow-up durations suggests that treatment outcomes can differ greatly between patients and studies. Decisions regarding secondary interventions should be individualized, considering patient-specific factors such as age, complications, and timing of intervention.
Extreme Risk Protection Orders—Ethics for Clinicians
Ashok, Vivek A., Knoepke, Christopher E. , Burnett, Joel R. , Pasha, Amirala S , Ashok, Vivek , Pasha, Amirala S.

Mayo Clinic

JAMA Internal Medicine | April 14, 2025 | Volume: 185 | Issue: 6 | Pages: 617

10.1001/jamainternmed.2025.0519 | PMID 40227703 Get It

This Viewpoint discusses clinicians as legal petitioners of extreme risk protection orders to promote the safety and well-being of patients and communities.
Implementation of a Multicancer Detection (MCD) Test in a Tertiary Referral Center in Asymptomatic Patients: An 18-Month Prospective Cohort Study
Ghosh, Aditya , Dougan, Brian M. , Gilman, Elizabeth A. , Salonen, Bradley R. , Bonnes, Sara L. , Andersen, Carl , Pasha, Amirala S. , Nanda, S. , Pagel, Erin M., Verness, Christina D., Crowley, Steven D. , Ressler, Steven W. , Samadder, Jewel, Chaudhuri, Aadel A. , Sánchez, William , Croghan, Ivana T. , Stephenson, Christopher R. , Ghosh, Karthik, Hurt, Ryan T. , Gilman, Elizabeth A , Adusumalli, Jay, Andersen, Carl A, Pasha, Amirala S , Pagel, Erin M , Samadder, Jewel J., Presutti, Richard J , Sanchez, William , Croghan, Ivana T , Ghosh, Aditya K , Ressler, Steven W , Adusumalli, Jayanth , Presutti, R. John

Mayo Clinic

Journal of Primary Care & Community Health | March 26, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251329290 | PMID 40132152 Get It

Objective: Multicancer Detection (MCD) tests, such as the GRAIL Galleri, offer a novel approach to cancer screening by detecting cancer-specific methylation patterns in cell-free DNA through a single blood sample. This study evaluated an 18-month implementation of MCD testing in a tertiary ambulatory internal medicine clinic. Patients and Methods: Between June 2022 and November 2023, 2244 asymptomatic (without symptoms attributed to cancer) patients underwent MCD testing. The study focused on operational workflows, patient and physician education, and diagnostic follow-up of positive results. Standardized materials, including electronic health record (EHR) workflows, FAQs, and diagnostic pathways, were developed to facilitate implementation. Challenges included managing false positives, patient anxiety, costs, and ethical considerations. Results: Of the 2244 patients tested, 17 (0.76%) had positive results, and 15 underwent further diagnostic evaluation. Cancer was confirmed in 11 (73.3%) patients, including cases of breast, colon, esophageal, lymphoma, ovarian, and pancreatic cancers. Four patients had no identifiable malignancy despite comprehensive work-up. Conclusions: MCD testing is feasible in routine clinical workflows, with 73% of positive cases yielding cancer diagnoses. While promising, further research is required to assess long-term outcomes, cost-effectiveness, and optimal implementation strategies of cancer interception in broader healthcare settings.
Recommitting to Housing and Health Care Justice After City of Grants Pass v Johnson
Habib, Anand , Stella, Sarah A. , Farkouh, Elizabeth K. , Grenko, Caleb M., Hart, Dionne , Pasha, Amirala S. , Habib, Anand R , Farkouh, E K , Pasha, Amirala S , Grenko, Caleb M.

Mayo Clinic

American Journal of Public Health | December 4, 2024 | Volume: 115 | Issue: 1 | Pages: 18-22

10.2105/ajph.2024.307870 | PMID 39631088 Get It

Challenges faced by international medical graduate (IMG) residents interested in hematology-oncology.
Juthani, Ronit , Khosla, Harshit , Deng, Lei , Dizman, Nazlı , Mittal, Kriti , Wu, Xia , Jose, Thulasee , Syed, Masood Pasha , Bakouny, Ziad , Choueiri, Toni K.

Mayo Clinic

JCO Oncology Practice | September 30, 2024 | Volume: 20 | Issue: 10_suppl | Pages: 29-29

10.1200/op.2024.20.10_suppl.29 Get It

29 Background: International Medical Graduates (IMGs) comprise over one-third of internal medicine (IM) trainees and practicing oncologists in the United States. We aimed to examine challenges faced by IM IMG residents in pursuing hematology-oncology (HO) fellowship positions. Methods: We conducted a pilot survey using SurveyPluto to assess demographics and evaluate visa related challenges amongst ACGME residents interested in HO. The survey was disseminated through the ASCO IMG Community of Practice (CoP), the Heme-Onc Fellows Mentorship Empowerment (H.O.M.E) group and the IMG Oncologists social media homepage (@IMG_Oncologists). Results: A total of 59 IMG residents completed the survey (20% PGY-1, 36% PGY-2 and 44% PGY-3). The majority of trainees (88%) were from community or university-affiliated community programs. J-1 visa was the most common visa type (67.8%). The visa process was rated as difficult or very difficult by 36% of trainees. Annual visa renewal was required by 51% trainees and 55.9% reported visa related impact on plans for research grant applications (Table). The greatest challenges associated with visa status were disruption of travel plans and inability to unite with family (35.6%); obtaining documentation from home country (33.9%); visa renewal (28.8%) and lack of clarity in visa instructions (27.1%). Among resources that respondents wanted better access to, IMG networking groups (81.4%), legal/financial aids (47.5%), institutional visa seminars (45.8%) and flexibility from their program to visit family overseas (45.8%) were identified as priorities. Conclusions: Visa related barriers pose significant challenges to IMGs interested in HO. Policy changes, advocacy work and additional resources could be beneficial for future IMG oncologists. Challenges associated with visa status for hematology/oncology aspirants. Greatest visa related barriers during training % of respondents (n=59) Documentation from home country 33.9% Disruption in travel plans/ inability to unite with family 35.6% Lack of clarity in renewal instructions/ renewal process post document procurement 55.9% Ability to secure grant affected by visa 22% Non-monetary grant aspects affected by visa 13.6% Did not pursue grants due to visa 20.3% Desired resources during residency Institutional visa seminars 45.8% IMG network groups 81.4% Program flexibility to visit family overseas/ legal and financial aids 45.8%/47.5%